# Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma

> **NCT04583020** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Camrelizumab
- **RADIATION:** radiation
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT04583020
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-12
- **Primary completion:** 2023-12-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2020-11-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04583020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04583020, "Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04583020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*